Cleveland BioLabs, Inc announced that the US Patent and Trademark Office has issued US Patent No. 7,638,485 titled 'Modulating Apoptosis' covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO), and two additional nations.

Cleveland BioLabs has also filed two additional new patent applications related to Protectan technology in the US around various aspects and properties for CBLB502 and related Protectan compounds, including new methods of use of flagellin derivatives and screening for new compounds with similar properties.

Yakov Kogan, chief operating officer of Cleveland BioLabs, noted, "With more than 13 sets of patents filed to date in the US and internationally around various properties of CBLB502 and related compounds, we believe we have protected the potentially broad uses of our Protectan technology. The receipt of our first US patent for protection from radiation is a major milestone in our development of CBLB502 and we continue to advance our work in this and other areas of protection from acute stresses."

CBLB502 is a derivative of a microbial protein, which has demonstrated the capacity to reduce injury from acute stresses, such as radiation in animal models.

Cleveland BioLabs is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses.